Skip to main content
. 2019 Feb 6;364:l240. doi: 10.1136/bmj.l240

Fig 1.

Fig 1

Flow diagram for prevalence episodes that started by 31 December 2014 including outcomes from per protocol follow-up until 31 May 2017 for women screened with high risk human papillomavirus (hrHPV) testing (A) and liquid based cytology (LBC) (B). CIN2+=cervical intraepithelial neoplasia grade 2 or worse